Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies

References

• Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000; 11: 8–17
   PubMed Web of Science ®Google Scholar
• Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001; 25: 43–50
   PubMed Web of Science ®Google Scholar
• Adachi Y, Aoki C, Yoshio-Hoshino N, Takayama K, Curiel D T, Nishimoto N. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 2006; 119: 1303–1311
   PubMed Web of Science ®Google Scholar
• King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006; 49: 561–568
   PubMed Web of Science ®Google Scholar
• Riera J R, Astengo-Osuna C, Longmate J A, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval [see comments]. Am J Surg Pathol 1997; 21: 1409–1419
   PubMed Web of Science ®Google Scholar
• Kushitani K, Takeshima Y, Amatya V J, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 2007; 57: 190–199
   PubMed Web of Science ®Google Scholar
• Yaziji H, Battifora H, Barry T S, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19: 514–523
   PubMed Web of Science ®Google Scholar
• Ordonez N G. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999; 30: 313–323
   PubMed Web of Science ®Google Scholar
• King J E, Thatcher N, Pickering C A, Hasleton P S. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48: 223–232
   PubMed Web of Science ®Google Scholar
• Ordonez N G. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003; 27: 1031–1051
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005; 129: 1407–1414
   PubMed Web of Science ®Google Scholar
• Ordonez N G. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007; 38: 1–16
   PubMed Web of Science ®Google Scholar
• Comin C E, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001; 32: 529–536
   PubMed Web of Science ®Google Scholar
• Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis. APMIS 1994; 102: 255–264
   PubMed Web of Science ®Google Scholar
• Battifora H, McCaughey W TE. Tumors of the Serosal Membranes. Atlas of Tumor Pathology, 3rd Series, Fascicle 15. Armed Forces Institute of Pathology, Washington, DC 1995
   Google Scholar
• Henderson D W, Shilkin K B, Langlois S L, Whitaker D. Malignant Mesothelioma. Hemisphere, New York 1992; 412
   Google Scholar
• Churg A, Cagle P T, Roggli V L. Tumors of the Serosal Membranes. American Registry of Pathology/Armed Forces Institute of Pathology, Washington, DC 2006
   Google Scholar
• Sporn T A, Roggli V L. Mesothelioma. Springer, New York 2004; 104–168
   Google Scholar
• Churg A, Roggli V, Galateau-Salle F, et al. Mesothelioma. IARC, Lyon 2004; 128–136
   Google Scholar
• Galateau-Sallé F, Brambilla E, Cagle P T, et al. Pathology of Malignant Mesothelioma. Springer, London 2006
   Google Scholar
• Breiman L, Friedman J H, Olshen R A, Stone C J. Classification and Regression Trees. Wadswoth & Brooks, Belmont, CA 1984
   Google Scholar
• Nurminen M. Prognostic models for delayed onset of renal allograft function. Internet J Epidemiol 2003; 1
   Google Scholar
• Venables W, Ripley B. Modern Applied Statistics with S-Plus. Springer, New York 2002
   Google Scholar
• Bateman A C, Al-Talib R K, Newman T, Williams J H, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1. Histopathology 1997; 30: 49–56
   PubMed Web of Science ®Google Scholar
• Barberis M C, Faleri M, Veronese S, Casadio C, Viale G. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997; 41: 1757–1761
   PubMed Web of Science ®Google Scholar
• Leers M P, Aarts M M, Theunissen P H. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998; 32: 209–216
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998; 11: 929–933
   PubMed Web of Science ®Google Scholar
• Abutaily A S, Addis B J, Roche W R. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002; 55: 662–668
   PubMed Web of Science ®Google Scholar
• Fetsch P A, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001; 25: 158–161
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003; 27: 150–158
   PubMed Web of Science ®Google Scholar
• Ordonez N G. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 2006; 19: 417–428
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000; 24: 598–606
   PubMed Web of Science ®Google Scholar
• Ordonez N G. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004; 35: 697–710
   PubMed Web of Science ®Google Scholar
• Sheibani K, Battifora H, Burke J S. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986; 123: 212–219
   PubMed Web of Science ®Google Scholar
• Sheibani K, Battifora H, Burke J S, Rappaport H. Leu-M1 antigen in human neoplasms: An immunohistologic study of 400 cases. Am J Surg Pathol 1986; 10: 227–236
   PubMed Web of Science ®Google Scholar
• Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 2001; 25: 610–617
   PubMed Web of Science ®Google Scholar
• Ordóñez N G. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989; 13: 276–291
   PubMed Web of Science ®Google Scholar
• Wick M R, Loy T, Mills S E, et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990; 21: 759–766
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases. Mod Pathol. 2006; 19: 373–383
   Google Scholar
• Battifora H. The Pleura. Raven Press, New York 1989; 829–855
   Google Scholar
• DiBonito L, Falconieri G, Colautti I, Bonifacio D, Dudine S. The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol 1992; 36: 329–332
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998; 29: 166–169
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol 1998; 109: 85–89
   PubMed Web of Science ®Google Scholar
• Miettinen O. Theoretical Epidemiology. Principles of Occurrence Research in Medicine. Wiley, New York 1985
   Google Scholar
• Greenland S. Summarization, smoothing, and inference in epidemiologic analysis. Scand J Soc Med 1993; 21: 227–231
   PubMedGoogle Scholar
• Ordonez N G. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002; 33: 953–967
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Value of cytokertin5/6 in distinguishing epithelial mesothelioma of pleura from lung adenocarcinoma. Am J Surg Pathol 1998; 22: 1215–1221
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998; 22: 1203–1214
   PubMed Web of Science ®Google Scholar
• Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997; 31: 140–143
   PubMed Web of Science ®Google Scholar
• Attanoos R L, Webb R, Dojcinov S D, Gibbs A R. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002; 40: 237–244
   PubMed Web of Science ®Google Scholar
• Foster M R, Johnson J E, Olson S J, Allred D C. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001; 125: 1316–1320
   PubMed Web of Science ®Google Scholar
• Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000; 36: 341–347
   PubMed Web of Science ®Google Scholar
• Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 2003; 199: 479–487
   PubMed Web of Science ®Google Scholar
• Amin K M, Litzky L A, Smythe W R, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995; 146: 344–356
   PubMed Web of Science ®Google Scholar
• Renshaw A A, Pinkus G S, Gorson J M. HBME-1 aids in distinguishing mesotheliomas and adenocarcinomas of the lung and breast. Mod Pathol 1995; 8: 152A
   Google Scholar
• Gonzalez-Lois C, Ballestin C, Sotelo M T, Lopez-Rios F, Garcia-Prats M D, Villena V. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001; 38: 528–534
   PubMed Web of Science ®Google Scholar
• Attanoos R L, Goddard H, Thomas N D, Jasani B, Gibbs A R. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Histopathology 1995; 27: 361–366
   PubMed Web of Science ®Google Scholar
• Ordonez N G. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol 1999; 112: 75–89
   PubMed Web of Science ®Google Scholar
• Skov B G, Lauritzen A F, Hirsch F R, Skov T, Nielsen H W. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies. Histopathology 1994; 25: 431–437
   PubMed Web of Science ®Google Scholar
• Szpak C A, Johnston W W, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986; 122: 252–560
   PubMed Web of Science ®Google Scholar
• Jordan D A, Jagirdar J, Kaneko M. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989; 135: 931–938
   PubMed Web of Science ®Google Scholar
• Hammar S P, Henderson D W, Klebe S, Dodson R F. Neoplasms of the pleura. Dail and Hammar's Pulmonary Pathology3rd ed., J FJ Tomashefski. Springer, New York 2008, Chapter 43
   Google Scholar